Display options
Cite
Ohshima K, Morii E. Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis. Metabolites. 2021;11(1)doi: 10.3390/metabo11010028.
Ohshima, K., & Morii, E. (2021). Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis. Metabolites, 11(1), . https://doi.org/10.3390/metabo11010028
Ohshima, Kenji, and Morii, Eiichi. "Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis." Metabolites vol. 11,1 (2021). doi: https://doi.org/10.3390/metabo11010028
Ohshima K, Morii E. Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis. Metabolites. 2021 Jan 02;11(1). doi: 10.3390/metabo11010028. PMID: 33401771; PMCID: PMC7824065.
Copy Download .nbib Format: NLM
Share it on

Metabolites. 2021 Jan 02;11(1). doi: 10.3390/metabo11010028.

Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis.

Metabolites

Kenji Ohshima, Eiichi Morii

Affiliations

  1. Department of Pathology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

PMID: 33401771 PMCID: PMC7824065 DOI: 10.3390/metabo11010028

Abstract

Cancer cells face various metabolic challenges during tumor progression, including growth in the nutrient-altered and oxygen-deficient microenvironment of the primary site, intravasation into vessels where anchorage-independent growth is required, and colonization of distant organs where the environment is distinct from that of the primary site. Thus, cancer cells must reprogram their metabolic state in every step of cancer progression. Metabolic reprogramming is now recognized as a hallmark of cancer cells and supports cancer growth. Elucidating the underlying mechanisms of metabolic reprogramming in cancer cells may help identifying cancer targets and treatment strategies. This review summarizes our current understanding of metabolic reprogramming during cancer progression and metastasis, including cancer cell adaptation to the tumor microenvironment, defense against oxidative stress during anchorage-independent growth in vessels, and metabolic reprogramming during metastasis.

Keywords: anchorage-independent growth; cancer metabolism; cancer metastasis; metabolic reprograming; therapeutic strategy; tumor microenvironments

References

  1. Science. 2019 Mar 15;363(6432):1217-1222 - PubMed
  2. Cell. 2014 Aug 28;158(5):1110-1122 - PubMed
  3. Nat Rev Cancer. 2011 Aug 11;11(9):671-7 - PubMed
  4. Science. 2018 Jun 1;360(6392):962-963 - PubMed
  5. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14542-7 - PubMed
  6. Annu Rev Physiol. 2020 Feb 10;82:103-126 - PubMed
  7. Cancer Cell Int. 2013 Sep 03;13(1):89 - PubMed
  8. Cell. 2015 Sep 10;162(6):1229-41 - PubMed
  9. Biochim Biophys Acta. 1990 Jun 26;1017(3):187-203 - PubMed
  10. Nat Med. 2017 Feb;23(2):235-241 - PubMed
  11. Cell Rep. 2016 Mar 8;14(9):2154-2165 - PubMed
  12. Cancer Res. 2015 Apr 15;75(8):1567-79 - PubMed
  13. Cell Rep. 2020 Oct 6;33(1):108231 - PubMed
  14. Cell Metab. 2019 Jun 4;29(6):1410-1421.e4 - PubMed
  15. Semin Cell Dev Biol. 2020 Feb;98:34-43 - PubMed
  16. Antioxid Redox Signal. 2007 Aug;9(8):1221-35 - PubMed
  17. Trends Mol Med. 2020 Jan;26(1):119-134 - PubMed
  18. J Biol Chem. 1988 Feb 25;263(6):2712-8 - PubMed
  19. Nat Commun. 2017 May 11;8:15267 - PubMed
  20. Mol Cancer. 2016 Jan 06;15:4 - PubMed
  21. Cell Metab. 2016 Nov 8;24(5):716-727 - PubMed
  22. Nat Genet. 2017 Mar;49(3):367-376 - PubMed
  23. Trends Cell Biol. 2017 Sep;27(9):645-657 - PubMed
  24. J Biol Chem. 2005 Jan 21;280(3):1754-63 - PubMed
  25. Cancer Res. 2007 Feb 15;67(4):1472-86 - PubMed
  26. Mol Pharm. 2011 Dec 5;8(6):2032-8 - PubMed
  27. Cancer Cell. 2013 Jun 10;23(6):709-11 - PubMed
  28. Oncogene. 2018 Apr;37(15):1949-1960 - PubMed
  29. Cancer Res. 2013 Mar 1;73(5):1524-35 - PubMed
  30. Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):2092-2098 - PubMed
  31. J Physiol. 2007 Dec 1;585(Pt 2):351-60 - PubMed
  32. Nature. 2020 Sep;585(7823):113-118 - PubMed
  33. Cell Metab. 2016 Mar 8;23(3):517-28 - PubMed
  34. Nature. 2020 Mar;579(7800):507-517 - PubMed
  35. Nature. 2019 Apr;568(7750):117-121 - PubMed
  36. Nature. 2007 Dec 20;450(7173):1235-9 - PubMed
  37. Oncogene. 2009 Aug 6;28(31):2796-805 - PubMed
  38. Cell Metab. 2019 Oct 1;30(4):720-734.e5 - PubMed
  39. Oncogene. 2016 Jul 14;35(28):3619-25 - PubMed
  40. Sci Rep. 2017 Mar 30;7:45504 - PubMed
  41. Mol Cell. 2008 May 23;30(4):393-402 - PubMed
  42. Cell. 2017 Feb 9;168(4):657-669 - PubMed
  43. Nature. 2019 Sep;573(7775):526-531 - PubMed
  44. Cancer Cell. 2018 Mar 12;33(3):347-354 - PubMed
  45. Semin Cell Dev Biol. 2020 Feb;98:15-25 - PubMed
  46. Cancer Cell. 2012 Mar 20;21(3):297-308 - PubMed
  47. Cell Chem Biol. 2017 Sep 21;24(9):1161-1180 - PubMed
  48. Cell Metab. 2019 Jul 2;30(1):201-211.e6 - PubMed
  49. Nat Metab. 2020 Dec;2(12):1369-1372 - PubMed
  50. Cell Rep. 2016 Oct 11;17(3):837-848 - PubMed
  51. Trends Cancer. 2016 Jun;2(6):295-304 - PubMed
  52. J Exp Clin Cancer Res. 2019 Sep 12;38(1):401 - PubMed
  53. Cell. 2007 Apr 6;129(1):111-22 - PubMed
  54. Cancer Res. 1996 Mar 15;56(6):1194-8 - PubMed
  55. Science. 2008 Sep 26;321(5897):1807-12 - PubMed
  56. Annu Rev Biomed Eng. 2017 Jun 21;19:163-194 - PubMed
  57. Nature. 2020 Oct;586(7831):790-795 - PubMed
  58. Nat Metab. 2019 Sep;1(9):858-860 - PubMed
  59. Nat Rev Mol Cell Biol. 2004 May;5(5):343-54 - PubMed
  60. Nat Cell Biol. 2018 Jul;20(7):775-781 - PubMed
  61. Trends Cancer. 2016 Jul;2(7):365-377 - PubMed
  62. Cancer Discov. 2013 Jun;3(6):648-57 - PubMed
  63. Elife. 2019 Apr 16;8: - PubMed
  64. Hepatology. 2016 Apr;63(4):1272-86 - PubMed
  65. Cell. 2015 Jul 16;162(2):259-270 - PubMed
  66. Nature. 2012 Aug 16;488(7411):337-42 - PubMed
  67. Science. 2019 Mar 15;363(6432):1222-1226 - PubMed
  68. Elife. 2014 Oct 01;3: - PubMed
  69. Nature. 2017 Feb 2;542(7639):119-123 - PubMed
  70. NMR Biomed. 2012 Nov;25(11):1234-44 - PubMed
  71. Cancer Cell. 2019 Feb 11;35(2):177-190.e8 - PubMed
  72. Cell. 2019 Jan 10;176(1-2):98-112.e14 - PubMed
  73. J Clin Invest. 2008 Dec;118(12):3930-42 - PubMed
  74. Cell. 2017 Apr 06;169(2):258-272.e17 - PubMed
  75. Nat Commun. 2019 Nov 1;10(1):5011 - PubMed
  76. Br J Cancer. 1992 Nov;66(5):919-24 - PubMed
  77. Nat Biotechnol. 2013 Jun;31(6):539-44 - PubMed
  78. Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):176-184 - PubMed
  79. Genes Dis. 2016 Dec 14;4(1):19-24 - PubMed
  80. Nat Metab. 2020 Jan;2(1):81-96 - PubMed
  81. Nature. 2018 Jul;559(7715):632-636 - PubMed
  82. Philos Trans R Soc Lond B Biol Sci. 2014 Feb 03;369(1638):20130099 - PubMed
  83. Cancer Res. 2016 Jun 1;76(11):3136-44 - PubMed
  84. Biochim Biophys Acta. 2011 Nov;1807(11):1432-43 - PubMed
  85. Proc Natl Acad Sci U S A. 2010 May 11;107(19):8788-93 - PubMed
  86. Cancer Res. 1962 Jun;22:581-8 - PubMed
  87. Nature. 2020 Jan;577(7788):115-120 - PubMed
  88. Biochim Biophys Acta. 2016 Mar;1863(3):382-391 - PubMed
  89. J Cereb Blood Flow Metab. 2016 Nov;36(11):1929-1941 - PubMed
  90. Cancer Cell. 2013 Jun 10;23(6):739-52 - PubMed
  91. Cancer Cell. 2020 Jun 8;37(6):767-785 - PubMed
  92. Mol Metab. 2020 Mar;33:48-66 - PubMed
  93. Br J Cancer. 2020 Jan;122(1):4-22 - PubMed
  94. Biochim Biophys Acta Bioenerg. 2017 Aug;1858(8):723-731 - PubMed
  95. Elife. 2017 Aug 15;6: - PubMed
  96. Nat Rev Mol Cell Biol. 2020 May;21(5):268-283 - PubMed
  97. Nature. 2016 Aug 31;537(7621):544-547 - PubMed
  98. Cell Rep. 2019 Oct 1;29(1):89-103.e7 - PubMed
  99. Br J Cancer. 2007 Sep 3;97(5):646-53 - PubMed
  100. Front Oncol. 2020 Apr 08;10:486 - PubMed
  101. Clin Exp Metastasis. 2012 Oct;29(7):657-62 - PubMed
  102. Cancer Res. 1994 Nov 1;54(21):5670-4 - PubMed
  103. Front Immunol. 2018 Feb 23;9:353 - PubMed
  104. Crit Rev Biochem Mol Biol. 2019 Jun;54(3):193-207 - PubMed
  105. Cell Metab. 2006 Mar;3(3):187-97 - PubMed
  106. Cell. 2014 Dec 18;159(7):1603-14 - PubMed
  107. Cancer Cell. 2020 Aug 10;38(2):167-197 - PubMed
  108. Nat Commun. 2020 Mar 24;11(1):1533 - PubMed
  109. Nat Cancer. 2020 Oct;1(10):998-1009 - PubMed
  110. Trends Cancer. 2015 Nov 1;1(3):161-173 - PubMed
  111. Neurochem Res. 2004 Jan;29(1):319-24 - PubMed
  112. Cell Metab. 2015 Jan 6;21(1):81-94 - PubMed
  113. Nat Metab. 2020 Nov;2(11):1212-1222 - PubMed
  114. Cancer Discov. 2020 Sep;10(9):1352-1373 - PubMed
  115. Immunity. 2002 Jun;16(6):769-77 - PubMed
  116. Nature. 2018 Feb 15;554(7692):378-381 - PubMed
  117. Sci Adv. 2020 Oct 9;6(41): - PubMed
  118. Nature. 2016 Apr 14;532(7598):255-8 - PubMed
  119. Nat Rev Cancer. 2007 Oct;7(10):763-77 - PubMed
  120. Cancer Res. 1967 Jun;27(6):1031-40 - PubMed
  121. Nature. 2019 Aug;572(7769):397-401 - PubMed
  122. Cancer Res. 2006 Jul 1;66(13):6699-707 - PubMed
  123. Nat Commun. 2018 Jul 31;9(1):2997 - PubMed
  124. Mol Cell. 2020 Jun 18;78(6):1034-1044 - PubMed
  125. Nat Metab. 2020 Feb;2(2):127-129 - PubMed
  126. Nature. 2019 Nov;575(7782):380-384 - PubMed
  127. N Engl J Med. 2009 Sep 10;361(11):1058-66 - PubMed
  128. PLoS One. 2014 Apr 25;9(4):e96183 - PubMed
  129. Lab Invest. 2018 Apr;98(4):449-461 - PubMed
  130. Science. 2019 Nov 22;366(6468):1013-1021 - PubMed
  131. Nature. 2013 May 30;497(7451):633-7 - PubMed
  132. Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):52-57 - PubMed
  133. Nature. 2017 Jan 5;541(7635):41-45 - PubMed
  134. Front Immunol. 2018 Aug 07;9:1816 - PubMed
  135. Nature. 2017 Nov 2;551(7678):115-118 - PubMed
  136. N Engl J Med. 2020 Feb 27;382(9):869-871 - PubMed
  137. Trends Cell Biol. 1995 Nov;5(11):424-8 - PubMed
  138. Int J Mol Sci. 2019 May 25;20(10): - PubMed
  139. Nat Rev Mol Cell Biol. 2010 Jan;11(1):50-61 - PubMed
  140. N Engl J Med. 1948 Jun 3;238(23):787-93 - PubMed
  141. Nat Rev Cancer. 2019 Nov;19(11):651-661 - PubMed
  142. Nat Cell Biol. 2018 Dec;20(12):1349-1360 - PubMed
  143. Sci Transl Med. 2010 Mar 31;2(25):25ra23 - PubMed
  144. Cancer Res. 2019 Apr 15;79(8):1952-1966 - PubMed
  145. Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6556-E6565 - PubMed
  146. Oncogene. 2014 Jul 3;33(27):3496-505 - PubMed
  147. Biomed Rep. 2018 Jan;8(1):3-10 - PubMed
  148. Int J Mol Sci. 2014 Jun 27;15(7):11539-54 - PubMed
  149. Nature. 2020 Sep;585(7824):288-292 - PubMed
  150. Trends Cancer. 2019 Nov;5(11):693-703 - PubMed
  151. Cell Metab. 2006 Mar;3(3):177-85 - PubMed
  152. Nat Cell Biol. 2008 Mar;10(3):295-305 - PubMed
  153. Nat Rev Cancer. 2020 Feb;20(2):74-88 - PubMed
  154. Mol Cancer. 2017 Apr 11;16(1):76 - PubMed
  155. N Engl J Med. 2009 Feb 19;360(8):765-73 - PubMed
  156. Nat Med. 2018 Jul;24(7):1036-1046 - PubMed
  157. Nat Cell Biol. 2014 Oct;16(10):992-1003, 1-15 - PubMed
  158. Clin Cancer Res. 2012 Oct 15;18(20):5546-53 - PubMed
  159. Nature. 2000 Sep 14;407(6801):249-57 - PubMed
  160. FASEB J. 2010 Oct;24(10):3903-15 - PubMed
  161. J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6 - PubMed
  162. Clin Cancer Res. 2006 Mar 1;12(5):1507-14 - PubMed
  163. Cell Rep. 2017 Feb 28;18(9):2228-2242 - PubMed
  164. Mol Cancer. 2009 Jun 26;8:41 - PubMed
  165. Cancer Res. 2003 Mar 1;63(5):1138-43 - PubMed
  166. Immunity. 2011 Dec 23;35(6):871-82 - PubMed
  167. Cell. 2017 Oct 5;171(2):358-371.e9 - PubMed
  168. J Exp Clin Cancer Res. 2019 Feb 4;38(1):52 - PubMed
  169. Nat Med. 1997 Feb;3(2):177-82 - PubMed
  170. Sci Adv. 2016 May 27;2(5):e1600200 - PubMed
  171. Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13409-14 - PubMed
  172. Br J Radiol. 2014 Mar;87(1035):20130676 - PubMed
  173. Oncogene. 2018 Apr;37(17):2285-2301 - PubMed
  174. Cell. 2016 Feb 11;164(4):681-94 - PubMed
  175. Science. 1956 Feb 24;123(3191):309-14 - PubMed
  176. Cancer Res. 2013 Jun 1;73(11):3285-96 - PubMed

Publication Types